RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and death
A case report and literature review examined the clinical course of a single 75-year-old female patient diagnosed with Waldenström macroglobulinemia and AL lambda-type amyloid nephropathy. The patient received chemotherapy consisting of rituximab, cyclophosphamide, and dexamethasone (the RCD regimen), alongside symptomatic supportive therapy. This intervention occurred within a clinical practice setting rather than a controlled trial environment.
Following treatment initiation, the patient demonstrated temporary improvement in clinical symptoms and laboratory parameters. However, this initial response was not sustained. The patient subsequently experienced rapid disease progression. Follow-up data were collected approximately three months after discharge.
The primary outcome of disease progression was unfavorable, culminating in the patient's death. The cause of death was attributed to multiple organ failure involving cardiac, renal, and respiratory dysfunction. No specific adverse events or tolerability data were reported beyond this fatal outcome. The study did not report statistical significance or confidence intervals, as is typical for single-patient case reports. Limitations inherent to this study design include the small sample size of one patient and the lack of a control group, which restricts the ability to draw broad causal conclusions. The findings may offer clinical guidance for similar rare cases but require cautious interpretation due to the lack of generalizability.